Portuguese Health Authority Grants Clever Leaves EU-GMP Certification for Post-Harvest Cannabis Flower

TOCANCIPÁ, Colombia – Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW), a multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced today that its facility in Portugal has been granted EU-GMP certification by the Portuguese Health Authority (INFARMED, I.P.) to manufacture dried cannabis flower as an active pharmaceutical ingredient and as finished product.

The EU-GMP certification is required for the registration and marketing of medicinal cannabis products in Europe and represents an important step toward broadening Clever Leaves’ ability to reach European patients with its own products. Additionally, the certification will bolster Clever Leaves’ commitment to supporting other cannabis companies in the region by providing a platform for achieving the necessary GMP standard for expansion into the European market.

Clever Leaves is one of few players in Portugal to receive EU-GMP certification for post-harvest cannabis flower in the format of API and finished product.

Andres Fajardo, Clever Leaves’ CEO, stated, “Receiving this certification and completing the rigorous process is an honor and accomplishment for Clever Leaves, from the initial design of the installations, through the qualification and validation of all equipment and processes, to the integration of the new unit’s quality procedures into the existing quality system of Clever Leaves Portugal. The fact that we were able to meet the highest of pharmaceutical standards in less than 10 months after completion of the new facility is a huge milestone for Clever Leaves and we could not be more proud of our team for their exemplary work.”

This certification marks a new milestone for the company and puts it in an advantageous position to open up new revenue streams while consolidating existing ones in the EMEA and Pacific regions.

(This information is primarily sourced from Clever Leaves.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).